Back to top
more

Valeant Pharmaceuticals International, Inc. (VRX)

(Real Time Quote from BATS)

$23.40 USD

23.40
6,571,593

-0.83 (-3.43%)

Updated Jul 13, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised

by Zacks Equity Research

Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.

    Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options

    by Zacks Equity Research

    Investors in Valeant Pharmaceuticals International, Inc. (VRX) need to pay close attention to the stock based on moves in the options market lately.

      Aerie Reports Positive Data on Ophthalmic Drug Rhopressa

      by Zacks Equity Research

      Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.

        Ryan McQueeney headshot

        Valeant (VRX) Stock Continues to Slump: Should You Buy the Dip?

        by Ryan McQueeney

        Shares of Valeant Pharmaceuticals (VRX) continued their slump on Wednesday, slipping another 5.4% during the morning trading hours. Is a bounce back imminent, or will Valeant continue its remarkable freefall?

          Why Is Valeant (VRX) Down 17.7% Since the Last Earnings Report?

          by Zacks Equity Research

          Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?

            by Zacks Equity Research

            Valeant Pharmaceuticals (VRX) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.

              Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?

              by Zacks Equity Research

              Options traders are pricing in a big move for Valeant Pharmaceuticals (VRX) shares as it has huge implied volatility.

                Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

                by Zacks Equity Research

                Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

                  Kevin Cook headshot

                  Biotech Bull Making a Comeback

                  by Kevin Cook

                  A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor

                    Valeant (VRX) Issues Notes, Restructures Debt; Shares Down

                    by Zacks Equity Research

                    Valeant Pharmaceuticals International, Inc. (VRX) commenced an offer to purchase cash up to $600 million of aggregate principal amount due 2018.

                      Parth Panchal headshot

                      Valeant (VRX) Stock Slides 4% on Debt Restructuring Announcement

                      by Parth Panchal

                      Pharmaceutical and biotech company Valeant Pharma (VRX) slipped down 4.33% to $12.50 intraday Monday due to an announcement of debt restructuring.

                        Should You Get Rid of Valeant Pharmaceuticals International (VRX) Now?

                        by Zacks Equity Research

                        Valeant Pharmaceuticals International (VRX) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.

                          Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View

                          by Zacks Equity Research

                          Valeant's (VRX) fourth-quarter results beat expectations but the guidance of 2017 was disappointing.

                            Arpita Dutt headshot

                            Pricing to Remain Pharma Headline Risk in 2017

                            by Arpita Dutt

                            Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

                              Is the Options Market Predicting a Spike in Valeant Pharmaceuticals International (VRX) Stock?

                              by Zacks Equity Research

                              Investors in Valeant Pharmaceuticals International, Inc. (VRX) need to pay close attention to the stock based on moves in the options market lately.

                                The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

                                  Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

                                  by Zacks Equity Research

                                  Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.

                                    The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

                                      Broadcom, Valeant Pharmaceuticals, Apple, Amazon and Netflix highlighted as Zacks Bull and Bear of the Day Broadcom, Valeant Pharmaceuticals, Apple, Amazon and Netflix highlighted as Zacks Bull and Bear of the Day

                                      by Zacks Equity Research

                                      Broadcom, Valeant Pharmaceuticals, Apple, Amazon and Netflix highlighted as Zacks Bull and Bear of the Day

                                        Kevin Cook headshot

                                        Bear of the Day: Valeant Pharmaceuticals (VRX)

                                        by Kevin Cook

                                        While analysts are encouraged about asset sales to reduce a 7X debt-to-equity ratio, they are still cutting EPS

                                          New Strong Sell Stocks for January 24th

                                          by Zacks Equity Research

                                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday

                                            Valeant Streamlines Portfolio with Skincare Brands Sale

                                            by Zacks Equity Research

                                            Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.

                                              Do Options Traders Know Something About Valeant Pharmaceuticals (VRX) Stock We Don't?

                                              by Zacks Equity Research

                                              Valeant Pharmaceuticals (VRX) warrants investors' attention based on moves in the options market lately.

                                                Valeant to Sell Dendreon Unit to Sanpower for $820 Million

                                                by Zacks Equity Research

                                                Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.

                                                  Is Valeant (VRX) Fated for Terrible 2017 As Well?

                                                  by Zacks Equity Research

                                                  Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.